Editas Medicine (NASDAQ:EDIT) is one of the best gene-editing stocks to buy according to hedge funds. On November 10, 2025, Clear Street raised its price target on Editas Medicine (NASDAQ:EDIT) to ...
The Budget targets ₹80,000 crore from disinvestment and asset monetisation in 2026-27, far above recent outcomes Market-based sales and infrastructure monetisation delivered most receipts, while ...
The average one-year price target for Editas Medicine (NasdaqGS:EDIT) has been revised to $4.95 / share. This is an increase of 22.78% from the prior estimate of $4.03 dated November 14, 2025. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results